- Home
- ELAB vs CDIO Comparison
ELAB vs CDIO Comparison
Compare ELAB & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- CDIO
- Stock Information
- Founded
- ELAB 2020
- CDIO 2017
- Country
- ELAB United States
- CDIO United States
- Employees
- ELAB N/A
- CDIO N/A
- Industry
- ELAB
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ELAB
- CDIO Health Care
- Exchange
- ELAB Nasdaq
- CDIO Nasdaq
- Market Cap
- ELAB 6.6M
- CDIO 7.0M
- IPO Year
- ELAB 2023
- CDIO N/A
- Fundamental
- Price
- ELAB $2.17
- CDIO $4.77
- Analyst Decision
- ELAB
- CDIO Buy
- Analyst Count
- ELAB 0
- CDIO 1
- Target Price
- ELAB N/A
- CDIO $60.00
- AVG Volume (30 Days)
- ELAB 77.7K
- CDIO 102.7K
- Earning Date
- ELAB 05-14-2025
- CDIO 05-15-2025
- Dividend Yield
- ELAB N/A
- CDIO N/A
- EPS Growth
- ELAB N/A
- CDIO N/A
- EPS
- ELAB N/A
- CDIO N/A
- Revenue
- ELAB N/A
- CDIO $19,902.00
- Revenue This Year
- ELAB N/A
- CDIO $1,434.82
- Revenue Next Year
- ELAB N/A
- CDIO $4,661.91
- P/E Ratio
- ELAB N/A
- CDIO N/A
- Revenue Growth
- ELAB N/A
- CDIO N/A
- 52 Week Low
- ELAB $1.95
- CDIO $3.40
- 52 Week High
- ELAB $939.96
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- ELAB 37.11
- CDIO 39.92
- Support Level
- ELAB $2.06
- CDIO $3.88
- Resistance Level
- ELAB $2.23
- CDIO $5.20
- Average True Range (ATR)
- ELAB 0.18
- CDIO 0.48
- MACD
- ELAB 0.05
- CDIO 0.32
- Stochastic Oscillator
- ELAB 29.92
- CDIO 68.25
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.